Glutamine supplementation in major surgery and intensive care

Luca Gianotti, Massimo Oldani, Sara Coppola, Luca Nespoli, Marco Zanello, Marco Braga

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Strong evidences suggest that glutamine (GLN) plays a key role of in several metabolic pathways and it has been recognized as an essential substrate for the appropriate function of many organs and the principal metabolic fuel for different rapidly dividing cells. Moreover, GLN is essential for cell metabolism because it is able to modulate gluconeogenesis, lipogenesis, anabolic processes, to preserve mitocondrial ATP levels and attenuate the activation of inducible nitric oxide synthase following ischemia, trauma and sepsis, and to maintain gut integrity. GLN supplementation might be important in stress conditions to maintain a stable tissue and plasma pool and improve the above pathways. The randomized clinical trials published so far evaluating GLN supplementation in elective surgical patients and in subjects receiving intensive care treatment - with few exceptions - suffer several important methodological limitations such as lack of sample size calculation, blindness, a priori definition of complications, intention-to-treat analysis, subgroup and post-hoc analysis, statistical underpower, and heterogeneous cohort enrollment. The protective effect of GLN supplementation on primary outcome measures, such as morbidity and mortality is not persuasive. The most methodologically robust trials evaluating GLN supplementation showed no benefits or even a trend to harm in specific subgroups. Up to now the available data do not support the routine use of GLN in elective surgical and in critically ill patients. Others large randomized trials are needed to clarify if there is any role for GLN supplementation in specific subgroups.

Original languageEnglish
Title of host publicationGlutamine in Clinical Nutrition
PublisherSpringer New York
Pages153-168
Number of pages16
ISBN (Print)9781493919321, 9781493919314
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Adenosinetriphosphate
Nitric oxide
Critical Care
Glutamine
Metabolism
glutamine
Surgery
Statistical methods
surgery
Chemical activation
Tissue
Plasmas
Substrates
Lipogenesis
Intention to Treat Analysis
randomized clinical trials
Gluconeogenesis
gluconeogenesis
Metabolic Networks and Pathways
blindness

Keywords

  • Artificial nutrition
  • Complications
  • Critical illness
  • Glutamine
  • Intensive care
  • Length of stay
  • Mortality
  • Nutritional support
  • Outcome
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Engineering(all)
  • Agricultural and Biological Sciences(all)

Cite this

Gianotti, L., Oldani, M., Coppola, S., Nespoli, L., Zanello, M., & Braga, M. (2015). Glutamine supplementation in major surgery and intensive care. In Glutamine in Clinical Nutrition (pp. 153-168). Springer New York. https://doi.org/10.1007/978-1-4939-1932-1_12

Glutamine supplementation in major surgery and intensive care. / Gianotti, Luca; Oldani, Massimo; Coppola, Sara; Nespoli, Luca; Zanello, Marco; Braga, Marco.

Glutamine in Clinical Nutrition. Springer New York, 2015. p. 153-168.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gianotti, L, Oldani, M, Coppola, S, Nespoli, L, Zanello, M & Braga, M 2015, Glutamine supplementation in major surgery and intensive care. in Glutamine in Clinical Nutrition. Springer New York, pp. 153-168. https://doi.org/10.1007/978-1-4939-1932-1_12
Gianotti L, Oldani M, Coppola S, Nespoli L, Zanello M, Braga M. Glutamine supplementation in major surgery and intensive care. In Glutamine in Clinical Nutrition. Springer New York. 2015. p. 153-168 https://doi.org/10.1007/978-1-4939-1932-1_12
Gianotti, Luca ; Oldani, Massimo ; Coppola, Sara ; Nespoli, Luca ; Zanello, Marco ; Braga, Marco. / Glutamine supplementation in major surgery and intensive care. Glutamine in Clinical Nutrition. Springer New York, 2015. pp. 153-168
@inbook{d40244fb240b4abc9dfab7a7489d9168,
title = "Glutamine supplementation in major surgery and intensive care",
abstract = "Strong evidences suggest that glutamine (GLN) plays a key role of in several metabolic pathways and it has been recognized as an essential substrate for the appropriate function of many organs and the principal metabolic fuel for different rapidly dividing cells. Moreover, GLN is essential for cell metabolism because it is able to modulate gluconeogenesis, lipogenesis, anabolic processes, to preserve mitocondrial ATP levels and attenuate the activation of inducible nitric oxide synthase following ischemia, trauma and sepsis, and to maintain gut integrity. GLN supplementation might be important in stress conditions to maintain a stable tissue and plasma pool and improve the above pathways. The randomized clinical trials published so far evaluating GLN supplementation in elective surgical patients and in subjects receiving intensive care treatment - with few exceptions - suffer several important methodological limitations such as lack of sample size calculation, blindness, a priori definition of complications, intention-to-treat analysis, subgroup and post-hoc analysis, statistical underpower, and heterogeneous cohort enrollment. The protective effect of GLN supplementation on primary outcome measures, such as morbidity and mortality is not persuasive. The most methodologically robust trials evaluating GLN supplementation showed no benefits or even a trend to harm in specific subgroups. Up to now the available data do not support the routine use of GLN in elective surgical and in critically ill patients. Others large randomized trials are needed to clarify if there is any role for GLN supplementation in specific subgroups.",
keywords = "Artificial nutrition, Complications, Critical illness, Glutamine, Intensive care, Length of stay, Mortality, Nutritional support, Outcome, Surgery",
author = "Luca Gianotti and Massimo Oldani and Sara Coppola and Luca Nespoli and Marco Zanello and Marco Braga",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1932-1_12",
language = "English",
isbn = "9781493919321",
pages = "153--168",
booktitle = "Glutamine in Clinical Nutrition",
publisher = "Springer New York",

}

TY - CHAP

T1 - Glutamine supplementation in major surgery and intensive care

AU - Gianotti, Luca

AU - Oldani, Massimo

AU - Coppola, Sara

AU - Nespoli, Luca

AU - Zanello, Marco

AU - Braga, Marco

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Strong evidences suggest that glutamine (GLN) plays a key role of in several metabolic pathways and it has been recognized as an essential substrate for the appropriate function of many organs and the principal metabolic fuel for different rapidly dividing cells. Moreover, GLN is essential for cell metabolism because it is able to modulate gluconeogenesis, lipogenesis, anabolic processes, to preserve mitocondrial ATP levels and attenuate the activation of inducible nitric oxide synthase following ischemia, trauma and sepsis, and to maintain gut integrity. GLN supplementation might be important in stress conditions to maintain a stable tissue and plasma pool and improve the above pathways. The randomized clinical trials published so far evaluating GLN supplementation in elective surgical patients and in subjects receiving intensive care treatment - with few exceptions - suffer several important methodological limitations such as lack of sample size calculation, blindness, a priori definition of complications, intention-to-treat analysis, subgroup and post-hoc analysis, statistical underpower, and heterogeneous cohort enrollment. The protective effect of GLN supplementation on primary outcome measures, such as morbidity and mortality is not persuasive. The most methodologically robust trials evaluating GLN supplementation showed no benefits or even a trend to harm in specific subgroups. Up to now the available data do not support the routine use of GLN in elective surgical and in critically ill patients. Others large randomized trials are needed to clarify if there is any role for GLN supplementation in specific subgroups.

AB - Strong evidences suggest that glutamine (GLN) plays a key role of in several metabolic pathways and it has been recognized as an essential substrate for the appropriate function of many organs and the principal metabolic fuel for different rapidly dividing cells. Moreover, GLN is essential for cell metabolism because it is able to modulate gluconeogenesis, lipogenesis, anabolic processes, to preserve mitocondrial ATP levels and attenuate the activation of inducible nitric oxide synthase following ischemia, trauma and sepsis, and to maintain gut integrity. GLN supplementation might be important in stress conditions to maintain a stable tissue and plasma pool and improve the above pathways. The randomized clinical trials published so far evaluating GLN supplementation in elective surgical patients and in subjects receiving intensive care treatment - with few exceptions - suffer several important methodological limitations such as lack of sample size calculation, blindness, a priori definition of complications, intention-to-treat analysis, subgroup and post-hoc analysis, statistical underpower, and heterogeneous cohort enrollment. The protective effect of GLN supplementation on primary outcome measures, such as morbidity and mortality is not persuasive. The most methodologically robust trials evaluating GLN supplementation showed no benefits or even a trend to harm in specific subgroups. Up to now the available data do not support the routine use of GLN in elective surgical and in critically ill patients. Others large randomized trials are needed to clarify if there is any role for GLN supplementation in specific subgroups.

KW - Artificial nutrition

KW - Complications

KW - Critical illness

KW - Glutamine

KW - Intensive care

KW - Length of stay

KW - Mortality

KW - Nutritional support

KW - Outcome

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84942441173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942441173&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1932-1_12

DO - 10.1007/978-1-4939-1932-1_12

M3 - Chapter

AN - SCOPUS:84942441173

SN - 9781493919321

SN - 9781493919314

SP - 153

EP - 168

BT - Glutamine in Clinical Nutrition

PB - Springer New York

ER -